Gainers

• TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
• Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 14.53% to $0.62.
• InnovAge Holding (NASDAQ:INNV) stock increased by 11.6% to $10.14. The market value of their outstanding shares is at $1.3 billion. As per the news, the Q1 earnings report came out 2 days ago.
• Pulmonx (NASDAQ:LUNG) stock rose 10.93% to $2.84. The market value of their outstanding shares is at $121.5 million.
• Doximity (NYSE:DOCS) shares increased by 7.59% to $35.7. The market value of their outstanding shares is at $6.2 billion. As per the news, the Q2 earnings report came out today.
• Nuvation Bio (NYSE:NUVB) shares increased by 6.68% to $4.47. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report came out yesterday.

Losers

• Inovio Pharmaceuticals (NASDAQ:INO) stock decreased by 16.5% to $1.21 during Thursday's after-market session. The company's market cap stands at $167.5 million.
• Orchestra BioMed Hldgs (NASDAQ:OBIO) shares decreased by 14.77% to $4.79. The company's market cap stands at $360.6 million.
• Accendra Health (NYSE:ACH) stock decreased by 11.95% to $0.26. The company's market cap stands at $21.0 million. As per the press release, Q3 earnings came out today.
• Verastem (NASDAQ:VSTM) shares decreased by 11.52% to $8.3. The market value of their outstanding shares is at $1.1 billion. As per the news, the Q3 earnings report came out today.
• Organogenesis Holdings (NASDAQ:ORGO) shares fell 9.23% to $0.76. The company's market cap stands at $111.9 million. As per the news, the Q3 earnings report came out today.
• Dentsply Sirona (NASDAQ:XRAY) stock declined by 8.75% to $9.21. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.